{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T15:49:00Z","timestamp":1744213740059},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2000,3,1]],"date-time":"2000-03-01T00:00:00Z","timestamp":951868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2000,3,1]],"date-time":"2000-03-01T00:00:00Z","timestamp":951868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2000,3,1]]},"DOI":"10.1038\/sj.leu.2401684","type":"journal-article","created":{"date-parts":[[2002,9,4]],"date-time":"2002-09-04T18:29:24Z","timestamp":1031164164000},"page":"379-388","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis"],"prefix":"10.1038","volume":"14","author":[{"given":"Y","family":"Kano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Akutsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Kon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2000,3,7]]},"reference":[{"key":"BF2401684_CR1","first-page":"3610","volume":"40","author":"RW Brockton","year":"1980","unstructured":"Brockton RW, Cheng YC, Stabile FM Jr, Montgomery JA . Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase Cancer Res 1980 40: 3610\u20133615","journal-title":"Cancer Res"},{"key":"BF2401684_CR2","first-page":"2587","volume":"42","author":"VI Avramis","year":"1982","unstructured":"Avramis VI, Plunkett W . Metabolism and therapeutic efficacy of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388 Cancer Res 1982 42: 2587\u20132591","journal-title":"Cancer Res"},{"key":"BF2401684_CR3","first-page":"474","volume":"21","author":"WC Tseng","year":"1982","unstructured":"Tseng WC, Derse D, Cheng YC, Brockman RW, Bennett LL Jr . In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells Mol Pharmacol 1982 21: 474\u2013477","journal-title":"Mol Pharmacol"},{"key":"BF2401684_CR4","doi-asserted-by":"crossref","first-page":"16617","DOI":"10.1016\/S0021-9258(17)46267-3","volume":"265","author":"P Huang","year":"1990","unstructured":"Huang P, Chubb S, Plunkett W . Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity J Biol Chem 1990 265: 16617\u201316625","journal-title":"J Biol Chem"},{"key":"BF2401684_CR5","first-page":"3","volume":"17","author":"W Plunkett","year":"1990","unstructured":"Plunkett W, Huang P, Gandhi V . Metabolism and action of fludarabine phosphate Semin Oncol 1990 17: (Suppl. 8) 3\u201317","journal-title":"Semin Oncol"},{"key":"BF2401684_CR6","doi-asserted-by":"publisher","first-page":"19428","DOI":"10.1074\/jbc.271.32.19428","volume":"271","author":"K Kamiya","year":"1996","unstructured":"Kamiya K, Huang P, Plunkett W . Inhibition of the 3\u2032 \u2192 5\u2032 exonuclease of human DNA polymerase epsilon by fludarabine-terminated DNA J Biol Chem 1996 271: 19428\u201319435","journal-title":"J Biol Chem"},{"key":"BF2401684_CR7","first-page":"4183","volume":"44","author":"JJ Hutton","year":"1984","unstructured":"Hutton JJ, Von Hoff DD, Kuhn J, Phillip J, Hersh M, Clark G . Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5\u2032-monophosphate (NSC 312887), a new purine antimetabolite Cancer Res 1984 44: 4183\u20134186","journal-title":"Cancer Res"},{"key":"BF2401684_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/jnci\/80.6.447","volume":"80","author":"JM Leiby","year":"1988","unstructured":"Leiby JM, Grever MR, Staubus AE, Neidhart JA . Malspeis L. Phase I clinical investigation of fludarabine phosphate by a loading-dose and continuous-infusion schedule J Natl Cancer Inst 1988 80: 447\u2013449","journal-title":"J Natl Cancer Inst"},{"key":"BF2401684_CR9","first-page":"2719","volume":"47","author":"JM Leiby","year":"1987","unstructured":"Leiby JM, Snider KM, Kraut EH, Metz EN, Malspeis L, Grever MR . Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5\u2032-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity Cancer Res 1987 47: 2719\u20132722","journal-title":"Cancer Res"},{"key":"BF2401684_CR10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V74.1.19.19","volume":"74","author":"MJ Keating","year":"1989","unstructured":"Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich EJ, McCredie KB . Fludarabine: a new agent with major activity against chronic lymphocytic leukemia Blood 1989 74: 19\u201325","journal-title":"Blood"},{"key":"BF2401684_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/JCO.1991.9.1.44","volume":"9","author":"MJ Keating","year":"1991","unstructured":"Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, Mccredie KB . Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia J Clin Oncol 1991 9: 44\u201349","journal-title":"J Clin Oncol"},{"key":"BF2401684_CR12","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1016\/0959-8049(95)00367-3","volume":"31A","author":"W Hiddemann","year":"1995","unstructured":"Hiddemann W . Non-Hodgkin's lymphomas \u2013 current status of therapy and future perspectives Eur J Cancer 1995 31A: 2141\u20132145","journal-title":"Eur J Cancer"},{"key":"BF2401684_CR13","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.1997.15.8.2780","volume":"15","author":"PA Dinndorf","year":"1997","unstructured":"Dinndorf PA, Avramis VI, Wiersma S, Krailo MD, Liu-Mares W, Seibel NL, Sato JK, Mosher RB, Kelleher JF, Reaman GH . Phase I\/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group J Clin Oncol 1997 15: 2780\u20132785","journal-title":"J Clin Oncol"},{"key":"BF2401684_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/bjc.1991.253","volume":"64","author":"JS Whelan","year":"1991","unstructured":"Whelan JS, Davis CL, Rule S, Ranson M, Smith OP, Mehta AB, Catovsky D, Rohatiner AZ, Lister TA . Fludarabine phosphate for the treatment of low grade lymphoid malignancy Br J Cancer 1991 64: 120\u2013123","journal-title":"Br J Cancer"},{"key":"BF2401684_CR15","first-page":"361","volume":"7","author":"L Elias","year":"1993","unstructured":"Elias L, Stock-Novack D, Head DR, Grever MR, Weick JK, Chapman RA, Godwin JE, Metz EN, Appelbaum FR . A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study Leukemia 1993 7: 361\u2013365","journal-title":"Leukemia"},{"key":"BF2401684_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/JCO.1993.11.1.116","volume":"11","author":"V Gandhi","year":"1993","unstructured":"Gandhi V, Estey E, Keating MJ, Plunkett W . Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy J Clin Oncol 1993 11: 116\u2013124","journal-title":"J Clin Oncol"},{"key":"BF2401684_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/JCO.1994.12.4.671","volume":"12","author":"E Estey","year":"1994","unstructured":"Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, Pierre S, Freireich EJ, Deisseroth A, Keating MJ . Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor J Clin Oncol 1994 12: 671\u2013678","journal-title":"J Clin Oncol"},{"key":"BF2401684_CR18","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1200\/JCO.1994.12.10.2051","volume":"12","author":"FM Foss","year":"1994","unstructured":"Foss FM, Ihde DC, Linnoila IR, Fischmann AB, Schechter GP, Cotelingam JD, Steinberg SM, Ghosh BC, Stocker JL, Bastian A, Phares JC, Sausville FA . Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides\/Sezary syndrome J Clin Oncol 1994 12: 2051\u20132059","journal-title":"J Clin Oncol"},{"key":"BF2401684_CR19","first-page":"943","volume":"9","author":"LE Robertson","year":"1995","unstructured":"Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Keating MJ . Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia Leukemia 1995 9: 943\u2013945","journal-title":"Leukemia"},{"key":"BF2401684_CR20","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1200\/JCO.1996.14.4.1262","volume":"14","author":"P McLaughlin","year":"1996","unstructured":"McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A, Swan F, Keating M, Cabanillas F . Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma J Clin Oncol 1996 14: 1262\u20131268","journal-title":"J Clin Oncol"},{"key":"BF2401684_CR21","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.1997.15.8.2780","volume":"15","author":"PA Dinndorf","year":"1997","unstructured":"Dinndorf PA, Avramis VI, Wiersma S, Krailo MD, Liu-Mares W, Seibel NL, Sato JK, Mosher RB, Kelleher JF, Reaman GH . Phase I\/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group J Clin Oncol 1997 15: 2780\u20132785","journal-title":"J Clin Oncol"},{"key":"BF2401684_CR22","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1046\/j.1365-2141.1997.4763281.x","volume":"99","author":"JE Parker","year":"1997","unstructured":"Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM, Samaratunga IR, Grace R, Gover PA, Mufti GJ . Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia Br J Haematol 1997 99: 939\u2013944","journal-title":"Br J Haematol"},{"key":"BF2401684_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/10428199709109160","volume":"26","author":"A Younes","year":"1997","unstructured":"Younes A, Rodriguez MA, McLaughlin P, North L, Sarris AH, Pate O, Hagemeister FB, Romaguera J, Preti A, Bachier C, Cabanillas F . Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma Leuk Lymphoma 1997 26: 77\u201382","journal-title":"Leuk Lymphoma"},{"key":"BF2401684_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1600-0609.1997.tb01694.x","volume":"59","author":"F Zaja","year":"1997","unstructured":"Zaja F, Rogato A, Russo D, Marin L, Silvestri F, Baccarani M . Combined therapy with Fludarabine and cyclophosphamide in relapsed\/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas Eur J Haematol 1997 59: 327\u2013328","journal-title":"Eur J Haematol"},{"key":"BF2401684_CR25","first-page":"45","volume":"4","author":"VI Avramis","year":"1998","unstructured":"Avramis VI, Wiersma S, Krailo MD, Ramilo-Torno LV, Sharpe A, Liu-Mares W, Kowck R, Reaman GH, Sato JK . Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I\/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group Clin Cancer Res 1998 4: 45\u201352","journal-title":"Clin Cancer Res"},{"key":"BF2401684_CR26","first-page":"3286","volume":"44","author":"A Sato","year":"1984","unstructured":"Sato A, Montgomery JA, Cory JG . Synergistic inhibition of leukemia L1210 cell growth in vitro by combinations of 2-fluoroadenine nucleosides and hydroxyurea or 2,3-dihydro-1H-pyrazole[2,3-a]imidazole Cancer Res 1984 44: 3286\u20133290","journal-title":"Cancer Res"},{"key":"BF2401684_CR27","first-page":"329","volume":"48","author":"V Gandhi","year":"1988","unstructured":"Gandhi V, Plunkett W . Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells Cancer Res 1988 48: 329\u2013334","journal-title":"Cancer Res"},{"key":"BF2401684_CR28","first-page":"992","volume":"7","author":"C Rayappa","year":"1993","unstructured":"Rayappa C, McCulloch EA . A cell culture model for the treatment of acute myeloblastic leukemia with fludarabine and cytosine arabinoside Leukemia 1993 7: 992\u2013999","journal-title":"Leukemia"},{"key":"BF2401684_CR29","first-page":"1072","volume":"47","author":"LY Yang","year":"1995","unstructured":"Yang LY, Li L, Keating MJ, Plunkett W . Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair Mol Pharmacol 1995 47: 1072\u20131079","journal-title":"Mol Pharmacol"},{"key":"BF2401684_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s002800050480","volume":"38","author":"S Loughlin","year":"1996","unstructured":"Loughlin S, Gandhi V, Plunkett W, Zwelling LA . The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells Cancer Chemother Pharmacol 1996 38: 261\u2013268","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF2401684_CR31","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1124\/mol.52.5.798","volume":"52","author":"L Li","year":"1997","unstructured":"Li L, Liu X, Glassman AB, Keating MJ, Stros M, Plunkett W, Yang LY . Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance Mol Pharmacol 1997 52: 798\u2013806","journal-title":"Mol Pharmacol"},{"key":"BF2401684_CR32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1046\/j.1365-2141.1998.00520.x","volume":"100","author":"B Bellosillo","year":"1998","unstructured":"Bellosillo B, Colomer D, Pons G, Gil J . Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells Br J Haematol 1998 100: 142\u2013146","journal-title":"Br J Haematol"},{"key":"BF2401684_CR33","first-page":"2","volume":"38","author":"U Koehl","year":"1997","unstructured":"Koehl U, Li L, Nowak B, Ruiz van Haperen V, Kornhuber B, Schwabe D, O'Brien S, Keating M, Plunkett W, Yang LY . Fludarabine and cyclophosphamide: synergistic cytotoxicity associated with inhibition of interstrand cross-link removal Proc Am Assoc Cancer Res 1997 38: 2","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF2401684_CR34","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/0145-2126(91)90112-7","volume":"15","author":"Y Kano","year":"1991","unstructured":"Kano Y, Sakamoto S, Kakahara T, Akutsu M, Inoue Y, Miura Y . In vitro effects of amsacrine in combination with other anti-cancer agents Leukemia Res 1991 15: 1059\u20131066","journal-title":"Leukemia Res"},{"key":"BF2401684_CR35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0360-3016(79)90044-0","volume":"5","author":"GG Steel","year":"1979","unstructured":"Steel GG, Peckham MJ . Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity Int J Radiat Oncol Biol Phys 1979 5: 85\u201393","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BF2401684_CR36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/ijc.2910300407","volume":"30","author":"K Kontula","year":"1982","unstructured":"Kontula K, Paavonen T, Vuopio P, Andersson LC . Glucocorticoid receptors in hairy-cell leukemia Int J Cancer 1982 30: 423\u2013426","journal-title":"Int J Cancer"},{"key":"BF2401684_CR37","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1126\/science.3486470","volume":"232","author":"J Erikson","year":"1986","unstructured":"Erikson J, Finger L, Sun L, ar-Rushdi A, Nishikura K, Minowada J, Finan J, Emanuel BS, Nowell PC, Croce CM . Deregulation of c-myc by translocation of the alpha-locus of the T-cell receptor in T-cell leukemias Science 1986 232: 884\u2013886","journal-title":"Science"},{"key":"BF2401684_CR38","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1084\/jem.162.6.2169","volume":"162","author":"M Maeda","year":"1985","unstructured":"Maeda M, Shimizu A, Ikuta K, Okamoto H, Kashihara M, Uchiyama T, Honjo T, Yodoi J . Origin of human T-lymphotrophic virus I-positive T cell lines in adult T cell leukemia J Exp Med 1985 162: 2169\u20132174","journal-title":"J Exp Med"},{"key":"BF2401684_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2739\/kurumemedj.42.149","volume":"42","author":"K Sagawa","year":"1995","unstructured":"Sagawa K, Koga T, Sasaguri Y, Sadamori N, Nagai K . A novel adult T cell leukemia-derived cell line (SALT-3) susceptible to human immunodeficiency virus type 1 infection Kurume Med J 1995 42: 149\u2013160","journal-title":"Kurume Med J"},{"key":"BF2401684_CR40","first-page":"351","volume":"48","author":"Y Kano","year":"1988","unstructured":"Kano Y, Ohnuma T, Okano T, Holland JF . Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture Cancer Res 1988 48: 351\u2013356","journal-title":"Cancer Res"},{"key":"BF2401684_CR41","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ijc.2910500420","volume":"50","author":"Y Kano","year":"1992","unstructured":"Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S, Miura Y . Effects of CPT-11 in combination with other anti-cancer agents in culture Int J Cancer 1992 50: 604\u2013610","journal-title":"Int J Cancer"},{"key":"BF2401684_CR42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s002800050790","volume":"42","author":"Y Kano","year":"1998","unstructured":"Kano Y, Akutsu M, Tsunoda S, Suzuki K, Adachi K . In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines Cancer Chemother Pharmacol 1998 42: 91\u201398","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF2401684_CR43","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1600-0609.1997.tb01694.x","volume":"59","author":"F Zaja","year":"1997","unstructured":"Zaja F, Rogato A, Russo D, Marin L, Silvestri F, Baccarani M . Combined therapy with Fludarabine and cyclophosphamide in relapsed\/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas Eur J Haematol 1997 59: 327\u2013328","journal-title":"Eur J Haematol"},{"key":"BF2401684_CR44","first-page":"612","volume":"104","author":"R Frewin","year":"1999","unstructured":"Frewin R, Turner D, Tighe M, Davies S, Rule S, Johnson S . Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders Br J Cancer 1999 104: 612\u2013613","journal-title":"Br J Cancer"},{"key":"BF2401684_CR45","first-page":"109","volume":"201","author":"J Kapelushnik","year":"1997","unstructured":"Kapelushnik J, Or R, Slavin S, Nagler A . A fludarabine-based protocol for bone marrow transplantation in Fanconi's anemia Bone Marrow Transplant 1997 201: 109\u2013110","journal-title":"Bone Marrow Transplant"},{"key":"BF2401684_CR46","first-page":"1559","volume":"28","author":"I Krakoff","year":"1968","unstructured":"Krakoff I, Brown NC, Reichard P . Inhibition of ribonucleoside diphosphate reductase by hydroxyurea Cancer Res 1968 28: 1559\u20131565","journal-title":"Cancer Res"},{"key":"BF2401684_CR47","first-page":"77","volume":"9","author":"JM Lundberg","year":"1990","unstructured":"Lundberg JM, Matthaeus WG, Chitamber CR . Gallium nitrate and fludarabine in combination synergistically inhibit the proliferation of human leukemia HL60 cells Pro Am Soc Clin Oncol 1990 9: 77","journal-title":"Pro Am Soc Clin Oncol"},{"key":"BF2401684_CR48","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0065-2571(85)90047-0","volume":"23","author":"JG Cory","year":"1985","unstructured":"Cory JG, Sato A, Carter GL, Bacon PE, Montgomery JA, Brown NC . The utility of combinations of drugs directed at specific sites of the same target enzyme-ribonucleotide reductase as the model Adv Enzyme Regul 1985 23: 181\u2013192","journal-title":"Adv Enzyme Regul"},{"key":"BF2401684_CR49","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","volume":"82","author":"M Hanada","year":"1993","unstructured":"Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC . bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia Blood 1993 82: 1820\u20131828","journal-title":"Blood"},{"key":"BF2401684_CR50","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1126\/science.7973635","volume":"266","author":"SW Lowe","year":"1994","unstructured":"Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T . p53 status and the efficacy of cancer therapy in vivo Science 1994 266: 807\u2013810","journal-title":"Science"},{"key":"BF2401684_CR51","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.V84.9.3148.3148","volume":"84","author":"E Wattel","year":"1994","unstructured":"Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P . p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies Blood 1994 84: 3148\u20133157","journal-title":"Blood"},{"key":"BF2401684_CR52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood.V81.1.151.151","volume":"81","author":"T Miyashita","year":"1993","unstructured":"Miyashita T, Reed JC . Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line Blood 1993 81: 151\u2013157","journal-title":"Blood"},{"key":"BF2401684_CR53","first-page":"1055","volume":"12","author":"A Thomas","year":"1996","unstructured":"Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, Newcomb EW . Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2\/bax proteins in drug resistance Oncogene 1996 12: 1055\u20131062","journal-title":"Oncogene"},{"key":"BF2401684_CR54","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/BF00685844","volume":"3","author":"P Huang","year":"1995","unstructured":"Huang P, Plunkett W . Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event Cancer Chemother Pharmacol 1995 3: 181\u2013188","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2401684.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2401684","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2401684.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T20:24:07Z","timestamp":1648758247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2401684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3,1]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,3,1]]}},"alternative-id":["BF2401684"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2401684","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3,1]]},"assertion":[{"value":"6 September 1999","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 1999","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2000","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}